Yildirim Mustafa, Kaya Vildan, Demirpence Ozlem, Gunduz Seyda, Bozcuk Hakan
Department of Medical Oncology, Ministry of Health Batman Regional Government Hospital, Batman, Turkey E-mail :
Asian Pac J Cancer Prev. 2015;16(1):327-32. doi: 10.7314/apjcp.2015.16.1.327.
Gastric cancer is one of the frequently seen cancers in the world and it is the second most common reason for death due to cancer. The prognostic role of expression of p53 detected by immunohistochemistry in gastric cancer remains controversial. This meta-analysis aimed to explore any association between overexpression and survival outcomes.
We systematically searched for studies investigating the relationships between expression of p53 detected by immunohistochemistry and prognosis of gastric cancer patients. Study quality was assessed using the Newcastle-Ottawa Scale. After careful review, survival data were extracted from eligible studies. A meta-analysis was performed to generate combined hazard ratios for overall survival and disease-free survival.
A total of 4.330 patients from 21 studies were included in the analysis. Our results showed tissue p53 overexpression in patients with gastric cancer to be associated with poor prognosis in terms of overall survival (HR, 1.610; 95% CI, 1.394 -5.235; p: <0.001). Pooled hazard ratio for disease free survival showed that p53 positivity or negativity were not statitistically significant (HR, 1.219; 95%CI, 0.782-1.899; p:0.382).
The present meta-analysis indicated overexpression of p53 detected by immunohistochemistry to be associated with a poor prognosis in patients with gastric cancer.
胃癌是全球常见的癌症之一,是癌症相关死亡的第二大常见原因。免疫组化检测的p53表达在胃癌中的预后作用仍存在争议。本荟萃分析旨在探讨p53过表达与生存结果之间的关联。
我们系统检索了研究免疫组化检测的p53表达与胃癌患者预后关系的研究。使用纽卡斯尔-渥太华量表评估研究质量。经过仔细审查,从符合条件的研究中提取生存数据。进行荟萃分析以生成总生存和无病生存的合并风险比。
分析纳入了来自21项研究的共4330例患者。我们的结果显示,胃癌患者组织p53过表达与总生存方面的不良预后相关(HR,1.610;95%CI,1.394 - 5.235;p:<0.001)。无病生存的合并风险比显示p53阳性或阴性无统计学意义(HR,1.219;95%CI,0.782 - 1.899;p:0.382)。
本荟萃分析表明,免疫组化检测到的p53过表达与胃癌患者的不良预后相关。